BYDUREON BCise exenatide 2 mg/.85mL Injection, Suspension, Extended Release, 4 cartridges — NDC 0310-6540-04 (Billing 00310-6540-04)
by AstraZeneca Pharmaceuticals LP · 4 CARTRIDGE in 1 CARTON / .85 mL in 1 CARTRIDGE
This is a package of 4 cartridges of BYDUREON BCise exenatide 2 mg/.85mL Injection, Suspension, Extended Release from AstraZeneca Pharmaceuticals LP, no longer marketed, no longer in the FDA NDC Directory; retail pharmacies pay about $234.22 per mL (NADAC). It is the main listing for this product, which comes in 2 package sizes.
NDC 00310-6540-04
🏷️ FDA NDC (as labeled)
0310-6540-04
billing pads the labeler segment with a zero
This package
Also priced by: Medicaid pays $239.79/unit — full pricing hub ↓
Main listing for product 0310-6540 · Also comes in:
1 cartridge 0310-6540-85
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Mar 13, 2024 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
NDC database record
One package, one record: these facts belong to NDC 0310-6540-04 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 0310 labeler · 6540 product · 04 package
- Barcode (UPC-A, from the NDC)
- 3 0310654004 4
- Medicaid fills, this package
- 14,884 prescriptions in the last four reported quarters
- FDA record last changed
- Mar 13, 2024
⚠️
Other active recalls for Exenatide (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Aug 28, 2026 — Defective Delivery System: Possibility of no medication in the prefilled pen. (Amneal Pharmaceuticals of New York, LLC) · FDA recall D-0868-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗
⚠️
Excluded from the active FDA NDC Directory.
The labeler reported this product as discontinued, so it is excluded from the active NDC Directory. The listing was last certified through Oct 2025. A label may still appear on DailyMed, but the NDC is no longer in the current FDA NDC Directory.
Search the FDA NDC Directory ↗
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
FDA NDC (as labeled)
0310-6540-04
Product NDC
0310-6540
11-digit billing NDC
00310654004
NCPDP billing unit
ML — per mL (volume)
Application #
NDA209210
Mechanism of action
GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists
DEA schedule
Non-controlled
Marketing category
NDA
Marketing status
Discontinued
FDA listing status
Discontinued by firm (certified through Oct 2025)
Route
SUBCUTANEOUS
Dosage form
INJECTION, SUSPENSION, EXTENDED RELEASE
Substance
EXENATIDE
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
GCN Seq No
077890
GCN
44039
HICL code
038451
Ingredient (HICL)
Exenatide Microspheres
HIC1 code
C
Therapeutic class — broad (HIC1)
Electrolyte Balance/Metabolism/Nutrition
HIC2 code
C4
Therapeutic class — intermediate (HIC2)
Antihyperglycemics
HIC3 code
C4I
Therapeutic class — specific (HIC3)
Antihypergly,Incretin Mimetic(Glp-1 Recep.agonist)
AHFS code
68:20.06.00
AHFS class
Incretin Mimetics
FDB label name
BYDUREON BCISE 2 MG AUTOINJECT
FDB brand name
Bydureon Bcise
Legend status
F — Federal legend — prescription drug or device
Quick answers
- GSN (GCN sequence number): 077890
- GCN: 44039
- HICL (First Databank): 038451
- AHFS class code: 68:20.06.00
Why two NDCs?
The FDA registers this code as 0310-6540-04 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00310-6540-04. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 8, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 8, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 8, 2026
Clinical
Label name BYDUREON BCISE 2 MG AUTOINJECT Ingredient Exenatide Microspheres
📖 What it is MedlinePlus · NLM
Exenatide injection is used with diet and exercise to lower blood sugar in certain people with type 2 diabetes (condition in which blood sugar is too high because the body does not make or use insulin normally). Exenatide is in a class of medications called incretin mimetics. It works by stimulating the pancreas to secrete insulin when blood sugar levels are high. Insulin helps move sugar from the blood into other body tissues where it is used for energy. Over time, people who have diabetes and high blood sugar can develop serious or life-threatening complications, including heart disease, s...
Read the full MedlinePlus article ↗Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Exenatide — tap one for details:
1
Nutrient depletion considerations
Exenatide may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
- MedlinePlus (NLM) · refreshed Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 8, 2026
💬 Questions about exenatide?
Ask a pharmacist →
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $234.220 | $796.35 / 3.4 ml |
| Medicaid paysCMS SDUD · 12 mo | $239.79 | $815.30 / 3.4 ml |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
NADAC price history (per mL) — tap or hover for the price & month
▲ Up 10% over the last 5 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
- CMS NADAC weekly file · file of Feb 18, 2026
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · through Q4 2025
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Marketing end | Status |
|---|---|---|---|---|---|---|
| 00310-6540-04 You're viewing this Main listing | 4 CARTRIDGE in 1 CARTON / .85 mL in 1 CARTRIDGE | $234.22 / mL | $796.35 | 2017-12-01 | — | Discontinued by firm |
| 00310-6540-85 0310-6540-85 | 1 CARTRIDGE in 1 CARTON / .85 mL in 1 CARTRIDGE | — | — | 2017-12-01 | — | Discontinued by firm |
In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in this package?
This package contains 4 cartridges — 4 cartridge in 1 carton / .85 ml in 1 cartridge.
How does this package differ from NDC 00310-6540-85?
Both are BYDUREON BCise exenatide 2 mg/.85mL Injection, Suspension, Extended Release — the drug itself is identical. This page's package is the 4 cartridges one, while NDC 00310-6540-85 is the 1 cartridge package.
What NDC number is used to bill for this package of BYDUREON BCise exenatide 2 mg/.85mL Injection, Suspension, Extended Release?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| BYDUREON BCise 2 mg/.85mLthis 00310-6540-04 | AstraZeneca | 4 cartridges | $234.220 | — | Discontinued | — |
About this product: this is the brand-name version. FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA Orange Book · refreshed Oct 9, 2026
- CMS NADAC weekly file · file of Feb 18, 2026
Availability & generic status
🏛️
2017
First FDA approval
Oct 2017
📍
2026
Currently FDA-listed
9 years listed
🛡️
2031
Latest patent/protection listed
not a guaranteed launch date
✅Generic appears available
FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.
🛡️ Latest patent/protection date listed: FDA patent/protection data lists protections through Apr 2031. This may affect when a full generic version becomes widely available, but it is not a guaranteed launch date.
Why the date isn’t exact: Generic timing can change because patents may be challenged, settled, licensed, added, removed, or worked around with a narrower label — and FDA approval does not always mean a pharmacy can get the generic today.
When could a generic Bydureon BCise arrive?
Our estimate: April 2031 about 4.5 years away
How sure: Toss-up. Still unsettled. Just as likely to slip as to hold.
Why then: A patent that protects the brand runs out. After that, approved generics can be sold.
See the full forecast for generic Bydureon BCise →Patents & exclusivity — FDA Orange Book
US 8501698 — method of use (U-2588)
US 6515117 — drug substance (U-2588)
US 8361972 — method of use (U-2588)
US 8329648 — method of use (U-2590)
US 8329648 — method of use (U-2593)
US 8329648 — method of use (U-2594)
US 8329648 — method of use (U-2596)
US 8329648 — method of use (U-2595)
US 8329648 — method of use (U-2588)
US 8329648 — method of use (U-2589)
US 8906851 — method of use (U-2590)
US 8906851 — method of use (U-2593)
US 8906851 — method of use (U-2597)
US 8906851 — method of use (U-2589)
US 9884092 — method of use (U-2593)
US 9884092 — method of use (U-2589)
US 9884092 — method of use (U-2594)
US 9884092 — method of use (U-2596)
US 9884092 — method of use (U-2597)
US 9884092 — method of use (U-2595)
US 9884092 — method of use (U-2590)
US 8895033 — method of use (U-2597)
US 8895033 — method of use (U-2590)
US 8895033 — method of use (U-2601)
US 8895033 — method of use (U-2589)
US 8895033 — method of use (U-2602)
US 8329648 — method of use (U-3189)
US 8329648 — method of use (U-3188)
US 8329648 — method of use (U-3190)
US 8895033 — method of use (U-3190)
US 8895033 — method of use (U-3188)
US 8895033 — method of use (U-3189)
US 8906851 — method of use (U-3188)
US 8906851 — method of use (U-3189)
US 8906851 — method of use (U-2588)
US 8906851 — method of use (U-3190)
US 9884092 — method of use (U-2588)
US 9884092 — method of use (U-3188)
US 9884092 — method of use (U-3190)
US 9884092 — method of use (U-3189)
US 8906851*PED — drug product
US 8329648*PED — drug product
US 8895033*PED — drug product
US 9884092*PED — drug product
US 8501698*PED — drug product
US 6515117*PED — drug product
US 8361972*PED — drug product
2017
2019
2021
2023
2025
2027
2029
2031
Substance patent
Formulation patent
Method-of-use patent
Exclusivity
Pediatric +6mo
🏛️FDA exclusivity
FDA-granted marketing protection. It’s separate from patents and may be shorter than patent protection.
🧪Product / substance patents
Patents covering the active ingredient, product, formulation, or related drug features.
🎯Method-of-use patents
Patents covering specific approved uses. These can sometimes be carved out with a “skinny label,” but not always.
🛈 What do these terms mean?
- Patent
- Legal protection listed in the Orange Book that may delay generic approval or launch. Issued by the U.S. Patent & Trademark Office.
- Substance patent
- Covers the active drug molecule itself — the hardest to design around. A generic generally can’t launch until it expires.
- Formulation (product) patent
- Covers a specific formulation or dosage form. A generic can sometimes work around it with a different formulation.
- Method-of-use patent
- A patent covering one specific approved use of the drug — not necessarily the whole molecule. A generic can sometimes launch with a “skinny label” that carves out the protected use and keeps the others.
- Skinny label
- A generic label that omits a still-patented use when the FDA allows it — letting a generic reach the market for the unprotected uses.
- Exclusivity
- FDA-granted marketing protection, separate from patents — e.g. 5-yr new chemical entity, 7-yr orphan drug, or a +6-month pediatric extension.
- Paragraph IV
- A generic applicant’s formal challenge to a listed patent. It can potentially lead to earlier generic entry, but often involves litigation or a settlement.
- RLD / RS
- Reference Listed Drug — the brand product the FDA uses as the reference for generic applications. Reference Standard — the product the FDA expects generics to compare against in bioequivalence testing.
- TE / AB rating
- FDA therapeutic-equivalence rating. An AB rating generally means the FDA considers a generic therapeutically equivalent to — and substitutable for — the brand.
- LOE (loss of exclusivity)
- The latest patent or exclusivity currently listed — the loss-of-exclusivity / latest-listed-protection date shown on this page. Paragraph-IV challenges and settlements can move the real date earlier; FDA approval and a manufacturer’s decision to market can move it later.
Built from the FDA Orange Book. The bars above are scaled to each protection’s expiry; the red LOE marker is the last one to lapse.
Listed patents (47)
| Patent | Type | Use code | Expires |
|---|---|---|---|
| US 8501698 ↗ | Method of use | U-2588 | Jun 20, 2027 |
| US 6515117 ↗ | Drug substance | U-2588 | Oct 4, 2025 |
| US 8361972 ↗ | Method of use | U-2588 | Mar 21, 2028 |
| US 8329648 ↗ | Method of use | U-2590 | Aug 18, 2026 |
| US 8329648 ↗ | Method of use | U-2593 | Aug 18, 2026 |
| US 8329648 ↗ | Method of use | U-2594 | Aug 18, 2026 |
| US 8329648 ↗ | Method of use | U-2596 | Aug 18, 2026 |
| US 8329648 ↗ | Method of use | U-2595 | Aug 18, 2026 |
| US 8329648 ↗ | Method of use | U-2588 | Aug 18, 2026 |
| US 8329648 ↗ | Method of use | U-2589 | Aug 18, 2026 |
| US 8906851 ↗ | Method of use | U-2590 | Aug 18, 2026 |
| US 8906851 ↗ | Method of use | U-2593 | Aug 18, 2026 |
| US 8906851 ↗ | Method of use | U-2597 | Aug 18, 2026 |
| US 8906851 ↗ | Method of use | U-2589 | Aug 18, 2026 |
| US 9884092 ↗ | Method of use | U-2593 | Aug 18, 2026 |
| US 9884092 ↗ | Method of use | U-2589 | Aug 18, 2026 |
| US 9884092 ↗ | Method of use | U-2594 | Aug 18, 2026 |
| US 9884092 ↗ | Method of use | U-2596 | Aug 18, 2026 |
| US 9884092 ↗ | Method of use | U-2597 | Aug 18, 2026 |
| US 9884092 ↗ | Method of use | U-2595 | Aug 18, 2026 |
| US 9884092 ↗ | Method of use | U-2590 | Aug 18, 2026 |
| US 8895033 ↗ | Method of use | U-2597 | Oct 4, 2030 |
| US 8895033 ↗ | Method of use | U-2590 | Oct 4, 2030 |
| US 8895033 ↗ | Method of use | U-2601 | Oct 4, 2030 |
| US 8895033 ↗ | Method of use | U-2589 | Oct 4, 2030 |
| US 8895033 ↗ | Method of use | U-2602 | Oct 4, 2030 |
| US 8329648 ↗ | Method of use | U-3189 | Aug 18, 2026 |
| US 8329648 ↗ | Method of use | U-3188 | Aug 18, 2026 |
| US 8329648 ↗ | Method of use | U-3190 | Aug 18, 2026 |
| US 8895033 ↗ | Method of use | U-3190 | Oct 4, 2030 |
| US 8895033 ↗ | Method of use | U-3188 | Oct 4, 2030 |
| US 8895033 ↗ | Method of use | U-3189 | Oct 4, 2030 |
| US 8906851 ↗ | Method of use | U-3188 | Aug 18, 2026 |
| US 8906851 ↗ | Method of use | U-3189 | Aug 18, 2026 |
| US 8906851 ↗ | Method of use | U-2588 | Aug 18, 2026 |
| US 8906851 ↗ | Method of use | U-3190 | Aug 18, 2026 |
| US 9884092 ↗ | Method of use | U-2588 | Aug 18, 2026 |
| US 9884092 ↗ | Method of use | U-3188 | Aug 18, 2026 |
| US 9884092 ↗ | Method of use | U-3190 | Aug 18, 2026 |
| US 9884092 ↗ | Method of use | U-3189 | Aug 18, 2026 |
| US 8906851*PED ↗ | Drug product | — | Feb 18, 2027 |
| US 8329648*PED ↗ | Drug product | — | Feb 18, 2027 |
| US 8895033*PED ↗ | Drug product | — | Apr 4, 2031 |
| US 9884092*PED ↗ | Drug product | — | Feb 18, 2027 |
| US 8501698*PED ↗ | Drug product | — | Dec 20, 2027 |
| US 6515117*PED ↗ | Drug product | — | Apr 4, 2026 |
| US 8361972*PED ↗ | Drug product | — | Sep 21, 2028 |
Common questions
Is there a generic version of BYDUREON BCISE 2 MG AUTOINJECT?
Yes — an FDA-approved generic equivalent is listed in the FDA Orange Book for BYDUREON BCISE 2 MG AUTOINJECT. See the alternatives section for substitutable, lower-cost products. An approval does not always mean it is on pharmacy shelves yet: we expect the first generic Bydureon BCise in April 2031, about 4.5 years away. See the forecast.
The FDA approved a generic — why can’t I get it at my pharmacy yet?
FDA approval and pharmacy availability are two different things. The FDA can approve a generic years before it actually reaches pharmacies, because the brand company may still hold patents or have a settlement that delays the launch. A manufacturer also has to choose to make and sell it, and have supply ready. So a drug can be “FDA-approved generic exists” and still be brand-only at the counter today.
Why do different websites show different generic release dates?
Generic availability is not based on one single date. Some sources use the first exclusivity expiration, some use the last product patent, and others use the latest method-of-use patent. Patent challenges, settlements, licenses, and label carve-outs can also change the real-world launch date. This page shows the underlying Orange Book dates so you can see why estimates may differ.
What does “FDA listed” mean?
It means the product appears in the FDA’s official NDC directory. That’s a good sign a product exists and is intended for the U.S. market, but on its own it does not confirm a pharmacy can fill it today. Where we have recent retail pricing data (NADAC) for a product, we label it “Availability likely” instead.
What does a patent or protection date mean here?
It’s the latest date currently listed in the FDA Orange Book for a patent or exclusivity on the brand product. It can affect when a full generic version becomes widely available — but it is not a guaranteed generic launch date. Generics sometimes arrive earlier (through a settlement or patent challenge) or later (a manufacturer still has to make and sell one).
What does “current Orange Book estimate” mean?
It means we are using the latest patent and exclusivity dates currently listed in the FDA Orange Book. It is not a guaranteed launch date.
Can a generic come out before the last patent expires?
Sometimes. A generic company may challenge a patent, settle with the brand manufacturer, receive a license, or obtain approval with a narrower label that avoids a patented use. In other cases, the last listed protection may delay full-label generic competition.
Can a generic come out after the listed dates?
Yes. Even after patents or exclusivity expire, a generic still needs FDA approval and a manufacturer must choose to market it. Supply, litigation, business decisions, or regulatory issues can delay actual availability.
What is the difference between patents and exclusivity?
Patents are legal protections usually issued by the U.S. Patent and Trademark Office. FDA exclusivity is marketing protection granted by the FDA. They are separate, and either one can affect generic timing.
Why are there multiple patent dates?
One drug can have several patents covering different things: the active ingredient, a formulation, a manufacturing process, or a specific approved use. That is why a page may show several expiration dates instead of one simple generic date.
Built from FDA Orange Book patent and exclusivity data. Dates are refreshed from public FDA data when available; the marker is max(latest patent expiry, latest exclusivity expiry). Paragraph-IV settlements and first-filer 180-day exclusivity can shift the real date; a method-of-use patent may allow an earlier skinny-label generic for non-protected indications. Generic launch timing is an estimate, not a guarantee.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.
- FDA Orange Book · refreshed Oct 9, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.- FDA label on DailyMed · label index refreshed Oct 8, 2026
- FDA openFDA NDC Directory · synced Oct 8, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
Manufacturer & labeler
LabelerAstraZeneca Pharmaceuticals LP
Application holderASTRAZENECA AB
FDA applicationNDA209210 (NDA)
Labeler code00310
Product typeHuman Prescription Drug
Portfolio113 products on file
More NDCs from AstraZeneca Pharmaceuticals LP labeler code 00310
- dapagliflozin and metformin hydrochloride 5 mg; 500 mg Tablet, Film Coated, Extended Release NDC 0310-6350-00
- dapagliflozin and metformin hydrochloride 5 mg; 1000 mg Tablet, Film Coated, Extended Release NDC 0310-6360-00
- dapagliflozin and metformin hydrochloride 10 mg; 500 mg Tablet, Film Coated, Extended Release NDC 0310-6370-00
- dapagliflozin and metformin hydrochloride 10 mg; 1000 mg Tablet, Film Coated, Extended Release NDC 0310-6380-00
- Byetta exenatide 250 ug/mL Injection NDC 0310-6512-01
- Byetta exenatide 250 ug/mL Injection NDC 0310-6524-01
- SymlinPen pramlintide acetate 1000 ug/mL Injection NDC 0310-6615-02
- Breztri budesonide, glycopyrrolate, and formoterol fumarate 160 ug; 18 ug; 4.8 ug Aerosol, Metered NDC 0310-6616-01
- SymlinPen pramlintide acetate 1000 ug/mL Injection NDC 0310-6627-02
- Budesonide and Formoterol Fumarate Dihydrate 160 ug; 4.5 ug Aerosol NDC 0310-7370-20
- Budesonide and Formoterol Fumarate Dihydrate 80 ug; 4.5 ug Aerosol NDC 0310-7372-20
- Crestor Rosuvastatin 5 mg Tablet, Film Coated NDC 0310-7560-90
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
- FDA openFDA NDC Directory · synced Oct 8, 2026
- Drugs@FDA
Full prescribing information FDA SPL
The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label ▾
No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.
No label section mentions that — try another word, or open the full label on DailyMed below.
Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.
Medicaid utilization & spend
📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
14.9K
Units reimbursed last 4 qtrs
50.7K
Gross reimbursed last 4 qtrs
$12.16M
Avg / prescription
$817.23
Avg / unit
$239.80
Latest quarter Q4 2025
0Rx
Medicaid pays / mL
$239.80
gross reimbursed
vs
NADAC / mL
$234.22
acquisition cost
=
Spread
+$5.5770
+2% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
Fee-for-service · 1,979 Rx Managed care · 12,905 Rx
State Medicaid map
Units reimbursed · per 100k residents
0.4219
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
Prescriptions—
Units—
Reimbursed—
🏆 Top states by units · per 100k residents
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.
Medicaid utilization by pack size
Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
Drug total (last 4 qtrs): 14,884 Rx · 50,725 units · $12,163,582 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.
Medicare Part D spend CMS · PART D · 2025 (Q1-Q4)
Medicare Part D (outpatient prescription) spending for Bydureon Bcise — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Bydureon Bcise. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Total Part D spend
$37.84M
Claims incl. refills
34K
Beneficiaries
14.9K
Spend / beneficiary
$2,534.05
Spend / claim
$1,114.32
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
Reported adverse events (FAERS)
Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Exenatide — the ingredient across all brands.
Top reported reactions
Age at onset
Reporter sex
Male · 36%
Female · 64%
Unknown · 0%
Serious outcomes
Reports over time (by year) — tap or hover for the count & year
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
About this NDC listing & data coverage
Finished prescription product
No longer marketed (per FDA listing data)
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | — Not published for this NDC No structured label is linked to this listing in DailyMed/openFDA. |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | ✓ Available |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | ✓ Available |
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.
Questions about this listing
Why is there no full label on this page?
No structured FDA label (SPL) is currently linked to this NDC in DailyMed/openFDA. That can happen with older listings, certain OTC and repackaged products, and recently updated listings whose label has not yet propagated. The listing itself is still valid — this page shows everything the public feeds provide for this package.
What does the discontinued status mean for this NDC?
The labeler reported a marketing end date (or the listing was delisted), so this specific package is no longer actively marketed. Remaining stock may still be dispensed for a time, and the NDC stays valid for historical records and claims — but data feeds (pricing, labeling) typically stop updating for it. Other package sizes or other manufacturers' versions of the same medication may still be marketed — see the equivalents section where available.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 1 cartridge (00310-6540-85). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
AstraZeneca Pharmaceuticals LP is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.